Emerging Microbes and Infections (Dec 2023)
Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination
- Rahul K. Suryawanshi,
- Taha Y. Taha,
- Maria McCavitt-Malvido,
- Ines Silva,
- Mir M. Khalid,
- Abdullah M. Syed,
- Irene P. Chen,
- Prachi Saldhi,
- Bharath Sreekumar,
- Mauricio Montano,
- Kafaya Foresythe,
- Takako Tabata,
- G. Renuka Kumar,
- Alicia Sotomayor-Gonzalez,
- Venice Servellita,
- Amelia Gliwa,
- Jenny Nguyen,
- Noah Kojima,
- Teresa Arellanor,
- Aallyah Bussanich,
- Victoria Hess,
- Maria Shacreaw,
- Lauren Lopez,
- Matthew Brobeck,
- Fred Turner,
- Yuzhu Wang,
- Sydney Ghazarian,
- Gregg Davis,
- Diviana Rodriguez,
- Jennifer Doudna,
- Lee Spraggon,
- Charles Y. Chiu,
- Melanie Ott
Affiliations
- Rahul K. Suryawanshi
- Gladstone Institutes, San Francisco, CA, USA
- Taha Y. Taha
- Gladstone Institutes, San Francisco, CA, USA
- Maria McCavitt-Malvido
- Gladstone Institutes, San Francisco, CA, USA
- Ines Silva
- Curative Inc., Monrovia, CA, USA
- Mir M. Khalid
- Gladstone Institutes, San Francisco, CA, USA
- Abdullah M. Syed
- Gladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA
- Irene P. Chen
- Gladstone Institutes, San Francisco, CA, USA
- Prachi Saldhi
- Department of Laboratory Medicine, University of California, San Francisco, CA, USA
- Bharath Sreekumar
- Gladstone Institutes, San Francisco, CA, USA
- Mauricio Montano
- Gladstone Institutes, San Francisco, CA, USA
- Kafaya Foresythe
- Department of Laboratory Medicine, University of California, San Francisco, CA, USA
- Takako Tabata
- Gladstone Institutes, San Francisco, CA, USA
- G. Renuka Kumar
- Gladstone Institutes, San Francisco, CA, USA
- Alicia Sotomayor-Gonzalez
- Department of Laboratory Medicine, University of California, San Francisco, CA, USA
- Venice Servellita
- Department of Laboratory Medicine, University of California, San Francisco, CA, USA
- Amelia Gliwa
- Department of Laboratory Medicine, University of California, San Francisco, CA, USA
- Jenny Nguyen
- Department of Laboratory Medicine, University of California, San Francisco, CA, USA
- Noah Kojima
- Curative Inc., Monrovia, CA, USA
- Teresa Arellanor
- Curative Inc., Monrovia, CA, USA
- Aallyah Bussanich
- Curative Inc., Monrovia, CA, USA
- Victoria Hess
- Curative Inc., Monrovia, CA, USA
- Maria Shacreaw
- Curative Inc., Monrovia, CA, USA
- Lauren Lopez
- Curative Inc., Monrovia, CA, USA
- Matthew Brobeck
- Curative Inc., Monrovia, CA, USA
- Fred Turner
- Curative Inc., Monrovia, CA, USA
- Yuzhu Wang
- Curative Inc., Monrovia, CA, USA
- Sydney Ghazarian
- Curative Inc., Monrovia, CA, USA
- Gregg Davis
- Curative Inc., Monrovia, CA, USA
- Diviana Rodriguez
- Curative Inc., Monrovia, CA, USA
- Jennifer Doudna
- Gladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA
- Lee Spraggon
- Curative Inc., Monrovia, CA, USA
- Charles Y. Chiu
- Department of Medicine, University of California San Francisco, San Francisco, CA, USA
- Melanie Ott
- Gladstone Institutes, San Francisco, CA, USA
- DOI
- https://doi.org/10.1080/22221751.2023.2270071
- Journal volume & issue
-
Vol. 12,
no. 2
Abstract
The emergence of SARS-CoV-2 recombinants is of particular concern as they can result in a sudden increase in immune evasion due to antigenic shift. Recent recombinants XBB and XBB.1.5 have higher transmissibility than previous recombinants such as “Deltacron.” We hypothesized that immunity to a SARS-CoV-2 recombinant depends on prior exposure to its parental strains. To test this hypothesis, we examined whether Delta or Omicron (BA.1 or BA.2) immunity conferred through infection, vaccination, or breakthrough infection could neutralize Deltacron and XBB/XBB.1.5 recombinants. We found that Delta, BA.1, or BA.2 breakthrough infections provided better immune protection against Deltacron and its parental strains than did the vaccine booster. None of the sera were effective at neutralizing the XBB lineage or its parent BA.2.75.2, except for the sera from the BA.2 breakthrough group. These results support our hypothesis. In turn, our findings underscore the importance of multivalent vaccines that correspond to the antigenic profile of circulating variants of concern and of variant-specific diagnostics that may guide public health and individual decisions in response to emerging SARS-CoV-2 recombinants.
Keywords
